Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment

QJM: An International Journal of Medicine

Volumn 105, Issue 1, 2012, Pages 69-75

  Seet, R C S ^a,b   Rabinstein, A A ^a  

^a MAYO CLINIC   (United States)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; FUROSEMIDE; GEMCITABINE; IRINOTECAN; LABETALOL; MANNITOL; NICARDIPINE; OXALIPLATIN; PACLITAXEL; PREDNISOLONE;

ARTICLE; BLOOD PRESSURE REGULATION; BRAIN EDEMA; BREAST METASTASIS; CLINICAL FEATURE; COLON CARCINOMA; COLORECTAL CANCER; DRUG MECHANISM; DRUG WITHDRAWAL; HEADACHE; HEPATOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY METASTASIS; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROIMAGING; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; RECTUM CARCINOMA; RETINA MACULA AGE RELATED DEGENERATION; SEIZURE; SIGMOID CARCINOMA; SYSTEMATIC REVIEW; VISCERAL METASTASIS; VISUAL DISORDER; VOMITING;

EID: 83755207590     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr139     Document Type: Article

References (23)

1. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010; 85:427-32.
2. Bartynski WS. Posterior reversible encephalopathy syndrome: part 2. Controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 2008; 29:1043-9.
3. Seet RC, Rabinstein AA, Lindell PE, Uhm JH, Wijdicks EF. Cerebrovascular events after bevacizumab treatment: an early and severe complication. Neurocrit Care 2011; doi:10.1007/s12028-011-9552-5.
4. Genentech IA. South San Francisco, CA: Genentech, Inc., 2009.
5. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333:328-35.
6. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980-2.
7. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980-2.
8. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006; 63:1475-8.
9. Burki F, Badie K, Bartoli P, Bernard P, Montastruc JL, Bagheri H. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br J Clin Pharmacol 2008; 65:793-4.
10. El Maalouf G, Mitry E, Lacout A, Lievre A, Rougier P. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol 2008; 255:295-6.
11. Levy CF, Oo KZ, Fireman F, Pierre L, Bania MA, Sadanandan S, et al. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer 2009; 52:669-71.
12. Koopman M, Muller EW, Punt CJ. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case. Dis Colon Rectum 2008; 51:1425-6.
13. Peter S, Hausmann N, Schuster A, Boehm HF. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab. Clin Experiment Ophthalmol 2008; 36:94-6.
14. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to agerelated maculopathy. J Ocul Pharmacol Ther 2010; 26:301-3.
15. Lau PC, Paunipagar B. Posterior reversible encephalopathy syndrome with bevacizumab. Hong Kong Med J 2011; 17:80-1.
16. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008; 65:205-10.
17. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108:2369-79.
18. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7:335-45.
19. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38:1258-64.
20. Rabinstein AA, Mandrekar J, Merrell R, Kozak OS, Durosaro O, Fugate J. Blood pressure fluctuations in posterior reversible encephalopathy syndrome. J Stroke Cerebrovasc Dis 2011; doi:10.1016/j.jstrokecerebrovasdis.2011.03.011.
21. Steeghs N, Rabelink TJ, op't Roodt J, Batman E, Cluitmans FH, Weijl NI, et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol 2010; 21:1100-5.
22. Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol 2008; 164:605-7.
23. Zamvar V, Sugarman ID, Tawfik RF, Macmullen-Price J, Puntis JW. Posterior reversible encephalopathy syndrome following infliximab infusion. J Pediatr Gastroenterol Nutr 2009; 48:102-5.